A randomised, controlled trial in progress in 14 United Kingdom and six Italian centres is evaluating screening for colorectal cancer using a single flexible sigmoidoscopy (FS) at around the age of 60 with removal during FS of all small adenomas, and colonoscopy for "high risk" polyps. The regimen aims to ensure that 95% of people (with either no polyps or only low risk polyps) complete the entire screening process in a single visit. This paper describes the rationale and design of the trial. Participants were patients aged between 55 and 64 on the lists of designated general practitioners (GPs) who were not excluded by their GP. A two stage recruitment procedure was employed to raise compliance rates in the intervention group. Potentially eligible persons were sent an "interest in screening" questionnaire; those who responded positively were randomised to the intervention or control groups. The trial is suYciently large to estimate within narrow confidence intervals the magnitude of benefit and the duration of eVect and optimum age for a single screen. It also examines the feasibility and acceptability of the screening regimen, and will identify training and quality assurance issues. Recruitment and screening are now complete and all baseline data have been collected. The first analysis of the eVect on colorectal cancer incidence and mortality rates and suitability for a national screening programme can be expected in 2004. (J Med Screen 2001;8:137-144) 
Colorectal cancer is the third most common cancer in both men and women and the second most frequent cause of cancer death in the United Kingdom. [2] [3] [4] [5] [6] The lifetime risk of developing the disease is 5% in both men and women, and it costs the NHS over £200 million annually to treat. 7 Of the more than 30 000 new cases diagnosed each year, 60% die of the disease within 5 years. Yet when detected at an early, localised stage, 90% can be cured, and when detected at the premalignant adenoma stage, cancer preventive treatment is virtually 100% eVective. 8 FAECAL OCCULT BLOOD TESTING In the United States, the United States Preventive Services Task Force has recommended that everyone over 50 should undergo annual faecal occult blood testing (FOBT) and periodic FS. 9 The guaiac based FOBT may reduce colorectal cancer mortality by up to 20% if oVered biennially [10] [11] [12] and possibly more if oVered annually. 13 Faecal occult blood testing is cheap and non-invasive, but 1%-2% will test positive each time the test is used and will then require colonoscopic investigation, leading to a lifetime colonoscopy rate of around 10%-20%. Disadvantages of FOBT are its low sensitivity and the requirement for frequent testing, which may limit compliance and thereby eVectiveness. Furthermore, repeat testing leads to high positivity rates. A pilot study is in progress in the United Kingdom to examine whether FOBT is suitable for inclusion in a National Health Service programme (http://www.doh.gov.uk/nsc/pdfs/summary). Results should be available within 3 years. SIGMOIDOSCOPY The 60 cm FS permits direct examination of the rectum and sigmoid colon, where 65% of colorectal cancers and adenomas are located. It is a more invasive test than FOBT, but paradoxically, comparative studies have found compliance rates with FS to be higher. 14 It takes only 5 minutes on average, requires no sedation, and only an enema to clear the distal bowel. 15 By preventing colorectal cancer through removal of adenomas, the costs of FS screening can be oVset against the costs of treatment. 16 As progression through adenoma to carcinoma is usually slow (more than 10 years), an added benefit of targeting the adenoma is that less frequent testing is required. A disadvantage is that FS does not examine the proximal colon, but distal appearances may be used to select a higher risk group for colonoscopy. COLONOSCOPY Several United States studies have recommended complete colonic screening by colonoscopy, 17 stating that one half of advanced neoplasms are missed by FS screening. However, advanced proximal lesions are found mainly at older ages, 17 18 and there is as yet no direct evidence that removing proximal adenomas prevents proximal colon cancer. In fact in two studies, 19 20 no additional benefit was found in reduction in incidence of colorectal cancer after colonoscopy compared with FS. Colonoscopy is currently unsuitable for mass population screening because it is invasive, expensive, and inconvenient, involving at least 36 hours of commitment in preparing the bowel and recovering from the sedation. Acceptance rates are low 17 21 and complication rates (haemorrhage and perforation) are higher than for FS. 22 The screening regimen in the trial The screening regimen we propose is described in figure 1 . Essentially, it has three components:
(1) A single flexible sigmoidoscopy screen at around age 60 years.
(2) Removal of small polyps (<1 cm) during FS screening.
(3) Colonoscopy for those found at FS screening to have "high risk" polyps and discharge for those found to have no polyps or only "low risk" polyps.
The rationale for each aspect is described below.
A SINGLE FLEXIBLE SIGMOIDOSCOPY SCREEN AT AROUND THE AGE OF 60 Over 90% of cases of colorectal cancer are diagnosed after the age of 55, so screening before 55 is unlikely to be cost eVective. About 25% of cases are diagnosed after the age of 80, but the expected life-years lost through colorectal cancer (around 3 23 ) are too few to make screening at that age worthwhile. Therefore population screening should aim to reduce incidence in the age group 55-80.
The aim of screening by FS is to diagnose and remove adenomas and thereby prevent the development of colorectal cancer. The prevalence of adenomas in the distal bowel increases with age from around 4% before age 50 to around 10% at the age of 60, after which there seems to be no further increase with advancing age. 1 This suggests that most distal adenomas will have developed by this age. If most colorectal cancers develop from adenomas, then most distal colorectal cancers (even in old age) must arise in those in whom an adenoma was acquired by the 6th decade. If we could Figure 1 The screening regimen. identify the age by which most susceptible persons will have acquired a distal adenoma, we could target this age for a once only sigmoidoscopy. Studies suggest that this age is around 60, but it might vary in populations with diVerent incidence rates and between men and women. The trial will investigate this by including all people in the age range 55-64 from a representative sample of general practices in the United Kingdom.
Discharge

Low risk polyps
This argument for "once only FS" cannot be used to justify a "once only" colonoscopy, as has been recommended 24 for the purpose of preventing both proximal and distal colon cancer, as proximal adenomas tend to arise later in life than distal adenomas 25 and their prevalence increases with age with no discernible plateau. 17 18 
REMOVAL OF SMALL POLYPS DURING FLEXIBLE
SIGMOIDOSCOPY
The current practice of referring all those with suspected adenomas for colonoscopy is unnecessary. Firstly, endoscopists are unable to diagnose adenomas, especially small ones, accurately. 26 This results in overreferral for colonoscopy as many polyps of adenomatous appearance are found on histological examination to be hyperplastic (considered to have no malignant potential). Moreover, small polyps detected at sigmoidoscopy often cannot be located again at colonoscopy. For this reason, small polyps detected on insertion of the FS should be removed immediately. Removal of polyps at FS may pose a risk of explosion because of combustible gases in the colon 27 but this risk is eliminated if carbon dioxide rather than air is used to insuZate the bowel.
SELECTIVE REFERRAL FOR COLONOSCOPY
Neoplasia in the proximal colon cannot be detected by sigmoidoscopy; however, adenomas in the distal colon are associated with a two-fold to three-fold increased prevalence of lesions in the proximal colon. 8 Undertaking colonoscopy in persons with adenomas detected at FS should detect some of these proximal lesions. For this reason some experts recommend colonoscopy whenever adenomas are detected. 28 However, not all distal adenomas are associated with an increased risk of proximal advanced neoplasia or of developing subsequent cancer. The most consistent predictive features are large size and villous histology. 8 29 The finding of only one or two small tubular adenomas seems to confer no increased risk of developing subsequent colorectal cancer compared with the general population. 8 30 In this trial, therefore, colonoscopy is reserved for people found to have large (1 cm), tubulovillous or villous adenomas in the distal bowel, a group which constitutes only 3%-5% of the population. 31 Also included in the "high risk" group are those with multiple (three) or severely dysplastic, small tubular adenomas. This is the only group with increased risk of advanced proximal or subsequent adenomas.
NEED FOR A RANDOMISED TRIAL
Evidence that sigmoidoscopy screening decreases of incidence of colorectal cancer or mortality from this disease is based mainly on case-control or uncontrolled cohort studies. 32 33 There have been two prospective trials, neither large enough to demonstrate an eVect of polyp removal on incidence rates. 34 35 The other studies could not eliminate the possibility that the lower incidence of colorectal cancer in people having sigmoidoscopy was the result of self selection by health conscious people with an inherently lower risk of the disease rather than an eVect of screening.
After calls for a randomised trial to evaluate a single FS screen, 1 36 two pilot studies (Welwyn Garden City, 3540 people; Leicester 19 706 people) 31 showed that such a trial was feasible, that the screening regimen was acceptable to the population, and that the yield of neoplasia was as predicted. A pilot study in Turin, Italy, 37 undertaken in 1170 people, had similar findings. The main trials, which include a further 12 centres in the United Kingdom and a further five centres in Italy, began in 1996. The Italian trial is using the United Kingdom protocol with minor modifications, and recruitment and screening are now complete in both countries.
Aims of the trial
The trial will examine the suitability of the screening regimen for inclusion in a national screening programme. Specific aims are:
x To measure the reduction in colorectal cancer incidence and mortality rates.
x To determine the duration of eVect of a single FS.
x To determine the optimum age for a single FS screen.
x To examine uptake rates, adverse eVects (including eVects on all cause mortality rates), psychological impact, cost eVectiveness, feasibility, and quality assurance issues.
Design of the trial
MEASURING EFFICACY
In measuring benefits, we need to draw a distinction between eYcacy and eVectiveness. EYcacy is the eVect of the screening test in those who use it. It is important to know for cost-benefit analyses the magnitude of eVectthat is, whether undergoing screening reduces risk by 20%, 50%, or 70%. EVectiveness is the eVect on the whole population of oVering the test; it measures the proportion of all colorectal cancers in the population that can be prevented by oVering the screening test and is relevant to all population based cancer screening programmes. EVectiveness depends not only on eYcacy, but also on uptake rates, the characteristics of compliers compared with the noncompliers, and the age range oVered screening. If compliers are a low risk group then increasing attendance among non-compliers will have disproportionate benefit in increasing eVectiveness. The current trial is examining the characteristics of the compliers and the non-compliers and at the end of the trial, eVectiveness can be modelled assuming diVerent compliance rates.
Randomised trials are usually analysed on an "intent to treat" basis. Incidence and mortality in the screening and control groups are compared as a whole, irrespective of whether persons have been screened. Ideally compliance (attendance for screening in the intervention group) is 100% and contamination (exposure to the screening procedure among the controls) is 0%. With decreasing compliance and increasing contamination, there is (1) a decrease in the power of a given sample size to show a statistically significant diVerence; (2) a masking of the true benefit of screening as the diVerence in incidence and mortality between the intervention and control groups no longer represents the diVerences in risk between screened and non-screened people. Methods exist to consider the second issue, but loss of power is unrecoverable. 38 It is important therefore to maximise attendance rates in the screened group and minimise exposure to the screening among the control group.
MAXIMISING COMPLIANCE WITH FLEXIBLE
SIGMOIDOSCOPY SCREENING
Verne et al 14 found that about 50% of people attend screening if the invitation comes from the GP with a specific appointment. We used this approach, and to increase compliance further recruitment occurred in two stages (see fig  2) . Trial participants included the 50%-60% of people who indicated interest in the test, who were then randomised to intervention or control groups.
This recruitment method may decrease the generalisability of the results, as participants may be healthier than non-responders. To investigate this the trial will compare incidence of colorectal cancer and mortalities in interested responders, not interested responders, and non-responders to the initial questionnaire. Baseline risk may vary between responders and non-responders, but it seems unlikely that there will be material diVerences in the eYcacy of FS. 
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DECREASING EXPOSURE OF THE CONTROL GROUP
TO SCREENING
The initial information sent to eligible people may increase the demand for screening among those who responded positively and were allocated to the control group. For this reason, centres were not included if local colorectal cancer screening initiatives were in place or planned, or open access FS was available. People were also excluded if they had undergone a colonic examination in the previous 5 years.
Size of the trial
REDUCTION IN INCIDENCE AND MORTALITY
The sample is large enough to determine within narrow confidence intervals the magnitude of benefit and to assess with reasonable power the duration of eVect, and the optimum age for a single screen. The most costly aspect of this trial is the screening procedure itself, estimated at £70/subject, including follow up colonoscopies for those with high risk polyps. To maximise the power achievable for a given number of screening examinations, the two stage recruitment procedure was used and the ratio of controls to those screened was increased to 2:1.
Estimates of the expected colorectal cancer rates in the control group were based on incidence (1988) and mortality (1992) rates for England and Wales. It was assumed that the rates for those expressing an interest in screening would be 20% below population rates and that no mortality would be found for the first 2 years because of exclusion of those with previously diagnosed colorectal cancer. Over the age range 55-64 it was assumed that the cumulative incidence and mortality would be around 1% at 10 and 15 years respectively.
A sample size of 195 000 is necessary (130 000 controls and 65 000 in the intervention group) to detect a 40% diVerence in the incidence of colorectal cancer at 10 years and in mortality at 15 years in each of the two main subgroups (age < 60, = 60 years). A 2 tailed test was used, with 90% power and a 5% level of significance. The sample size calculations assumed conservatively that 55% would comply with screening and that 5% of the controls would undergo screening. To allow for lead time, it was also assumed that there would be no reduction in incidence in the first 2 years as most cancers would be detected asymptomatically at screening.
DURATION OF PROTECTION
The trial is big enough to detect moderately large diVerences in the incidence rates over years 1-5 versus years 6-10. For example, if interval distal colon cancer rates in those actually screened are 25% of expected rates in years 1-5 and only 50% of expected rates in years 6-10, this diVerence will be detected with 57% power. A more detailed analysis will be done using follow up time as a continuous variable in a logistic regression, which will increase the power further.
OPTIMUM AGE FOR SCREENING
The age at which screening occurs is a crucial variable when screening is only oVered once. Subsequent protection is greater at older ages because more adenomas will have appeared; however, screening at an older age does not protect against cancers developing before the age of screening. Adenoma prevalence in the distal colon seems to increase with age until around 60, after which there is no further increase. This suggests that the incidence of new adenomas in the distal colon decreases rapidly after the age of 60, although another explanation is that the regression rate balances the incidence rate of new adenomas. The earliest time at which the adenoma prevalence plateaux should give the most benefit in terms of preventing cancer by adenoma removal.
It is therefore necessary to find the age at which the increase in prevalence of adenomas is not significantly diVerent from zero. The sample invited for screening was spread evenly over the eligible age range 55-64 years to permit comparison of prevalence between the ages of 55 and 60 and between 60 and 65. Women seem to develop adenomas later than men, so separate estimates are required for each sex. With 40 000 people undergoing screening and a roughly 10% overall adenoma rate, there will be suYcient power to estimate a change in slope between each 5 year period separately for men and women with a 95% confidence interval of about 1.5%. Thus an increase from say 8% at the age of 55 to 10% at the age of 60 would be reliably detected.
FOLLOW UP METHODS
Those with high risk polyps at FS will undergo at least two follow up colonoscopies at 3 yearly intervals. If more than five polyps or a polyp larger than 2 cm are found, an additional colonoscopy will be oVered at 12 months.
The primary end points of the study are incidence of colorectal cancer and death. The entire cohort is regularly matched against the data held by the NHS Central Register for deaths and cancer incidence. To provide more immediate ascertainment of new cancer registrations, the trial cohort will also be matched against data held by local cancer registries in the trial regions. In future it is planned to match the data to the national minimum dataset of all inpatient and outpatient activity. All adverse events which are possibly related to any aspect of the screening procedure have been documented. These are defined as any symptom or sign which develops or increases in severity after any procedure. A serious adverse event is an event which is fatal, life threatening, or requires or prolongs the stay in hospital. Adverse eVects have been reported to the trial centre by patients, their GPs, or other hospital departments, and in mailed questionnaires completed on the morning after the test and at 3, 6, and 12 months in a large sample of participants. An independent data monitoring committee examined all serious adverse effects.
Ultimately the most important measure when assessing an intervention is the ratio of benefit to harm. In the FOBT trial in Nottingham, for every 10 persons in whom death from colorectal cancer was prevented, one extra person died as a result of the screening procedure. 39 We shall not be able to estimate this ratio for FS screening until we have results on colorectal cancer specific and all cause mortality in the intervention and control groups.
COMPLIANCE, ACCEPTABILITY, AND PSYCHOLOGICAL IMPACT
Evaluation of psychosocial factors associated with participation in a new screening programme is an essential component of the trial. We examined the psychosocial factors which were associated with the initial expression of interest in screening in the population and subsequent attendance for screening among those who have expressed an interest in the pilot centres. [40] [41] [42] A pilot intervention study was then undertaken with the aim of reducing the perceived barriers to screening by manipulation of the information provided to participants. 43 Potential adverse psychological eVects that might result from participating in an FS screening programme include anxiety induced by raising awareness about personal risk of bowel cancer, 44 embarrassment or pain arising from the test, 45 and anxiety resulting from being found to have polyps or cancer or requiring colonoscopy or surgery. Conversely a negative test or observing the complete removal of polyps may engender a feeling of relief. To measure these eVects, relevant questions were included in both baseline and follow up questionnaires sent at 3 months to all participants undergoing screening as part of the routine surveillance of the acceptability and impact of screening. To track the time scale of any adverse eVects, follow up questionnaires were sent at 6 and 12 months in two of the trial centres. An additional aim was to identify the characteristics of those who are distressed after screening.
QUALITY AND SAFETY OF ENDOSCOPY
Sigmoidoscopic screening can reduce incidence and mortality rates only if polyps destined to become malignant are safely detected and removed. Flexible sigmoidoscopy and polyp removal are generally low risk procedures when performed by experienced endoscopists, but are occasionally associated with complications, which can be severe or fatal. Three specialist groups were established in the fields of endoscopy, surgery and histopathology as part of the trial to develop precise guidelines for the safe and eVective performance of all procedures undertaken in the screening context. In addition, the trial was designed to permit examination of factors aVecting performance of FS. All examinations were recorded on videotape, so that if a cancer is subsequently detected within reach of the sigmoidoscope the videotape can be reviewed to determine the likelihood that the cancer or its precursor lesion was present at the time of screening. A single endoscopist at each trial centre undertook around 3000 examinations, all using identical endoscopy equipment which was purchased for the trial. As incidence rates should not vary substantially between centres, and the age range and sex ratios of those screened were the same in each centre, there should be little variation in the true rates of adenomas between centres. Any variability should therefore be due to diVerences in the quality of performance of the endoscopic examinations. ECONOMICS We are measuring the costs of the screening procedure as oVered and modelling the costs of diVerent strategies for the delivery of FS screening. Components of costs include those associated with the procedures (FS, colonoscopy, and surgery), the histopathological assessment of polyps, and attendant administrative costs. Examination costs are dependent on staYng requirements, equipment costs (including capital outlay, depreciation, and maintenance), consumables, and overheads. The overall cost of procedures is also dependent on the number of people screened per session, polypectomy rate, number of polyps requiring histological assessment, and the referral rate for colonoscopy and surgery. Ways of optimising these will be examined as well as a sensitivity analysis of the unit costs and numbers of events on the overall programme cost. The administrative costs associated with the invitation for screening, communication of results to participants and their GPs, and extra costs resulting from additional visits to the GP and to specialist units for coincidentally detected colorectal pathology will also be measured.
WORKLOAD
To achieve uniformly high standards, screening should be undertaken in large, dedicated screening units. An independent report on FS screening 36 predicted the workload for a population of 400 000 if a single sigmoidoscopy screen were implemented nationally: 4000 persons would need to be invited each year and, assuming a 70% compliance rate, 2800 sigmoidoscopies would be performed (56 each week, which would require five dedicated FS sessions).
In the trial, each centre screened 48 people each week in four dedicated sessions (12 examinations per session), with one additional session each week devoted to the colonoscopies required for those found to have high risk adenomas. To ensure that 12 people attended for each session, 18 invitations were issued. Logistically it seems feasible to oVer the population a single FS examination at around the age of 60 years.
Auxiliary studies
NEED FOR COLONOSCOPY IN PEOPLE WITH A
STRONG FAMILY HISTORY OF COLORECTAL CANCER If a national screening programme were implemented and if, as has been suggested, 46 colonoscopy were required for people aged 55 years or more who have a strong family history, it would be necessary to ask at the time of invitation about family history and make provision for colonoscopy screening for those with a strong family history. Conversely, if colonoscopy was not required, as has also been suggested, 47 and FS screening was considered suYcient in this group, the costs of a national screening programme would be reduced considerably. To consider this question, the prevalence of neoplasia in the proximal colon (beyond the reach of the sigmoidoscope) has been compared in around 400 trial participants with a strong family history and an equivalent number of age and sex matched controls.
ENVIRONMENTAL RISK FACTORS
A link between diet and colorectal cancer has long been suspected, but the specific nutrients or food items implicated and the stage at which they act in the development of the disease are disputed. In four trial centres, 12 000 screening participants (97% of those who were asked) completed a short food frequency questionnaire (FFQ) of 28 items with questions taken from a format published elsewhere. 48 The FFQ also includes questions on smoking and alcohol consumption, and dietary results have been compared with those obtained from a detailed 7 day dietary diary. 49 A questionnaire on current medication, associated medical conditions, operations, and bowel symptoms was completed by the entire cohort undergoing screening in the trial. Associations between the presence of adenomas and dietary, tobacco, and pharmaceutical exposures, as well as health conditions will be explored.
ENVIRONMENT-GENE INTERACTIONS
The eVects of dietary exposure on risk of colorectal cancer may be modulated by inherited polymorphism in various genes aVecting nutrient and xenobiotic metabolism. Most studies have focused on colorectal cancers, rather than adenomas, and have included only a few cases and controls. In the current study, blood samples have been collected from 900 persons found at screening to have adenomas and from 900 age and sex matched controls. Several polymorphisms in phase 1 and phase 2 enzymes are being analysed including N-acetyltransferases (NAT1 and NAT2), cytochrome P450 (Cyp1A1, Cyp1A2, and Cyp2E1), glutathione-S-transferases (GSTM1, GSTM3, and GSTT1), microsomal epoxide hydrolase, methyl tetrahydrofolate reductase, and ApoE. In a collaboration with the European prospective investigation into cancer (EPIC), malondialdehyde DNA adduct concentrations are being measured in colonic biopsies from 80 people with adenomas and 80 polyp-free controls.
Conclusion
The main aim of screening by FS is to detect and remove adenomas, which are the assumed precursors to most colorectal cancers, and thereby to prevent the development of cancer. This trial has been designed to determine eYciently (with high power for given funding) the magnitude of reduction in incidence and mortality that can be achieved by oVering a single FS screen to men and women aged between 55 and 64 years. A multidisciplinary approach has been adopted to answer some practical questions about the safety, acceptability, and feasibility of the screening regimen, in addition to providing an opportunity to answer some important scientific questions about the aetiology and risk factors for development and progression of adenomas. The trial can be considered a success in that it has progressed as planned and on schedule, with 170 497 recruited to the trial and 40 674 screened. Baseline data collection is now complete and all that is required is to analyse the wealth of data collected, and to wait for 4 years, when the first analysis on incidence and mortality can be undertaken.
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